ProCE Banner Activity

Practical Insights for NPs and PAs: Biomarker Testing in NSCLC

Clinical Thought

Expert faculty discuss the importance of comprehensive molecular profiling in NSCLC and the impact of actionable biomarkers on treatment selection.

Released: June 05, 2023

Share

Faculty

Rasheda Persinger

Rasheda Persinger, MSN, AGNP-C, AOCNP

Medical Oncology Lead Nurse Practitioner
Sidney Kimmel Cancer Center Sibley Memorial Hospital
Johns Hopkins System
Washington, DC

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Learning Objectives

  • Identify actionable biomarkers and their impact on non-small-cell lung cancer (NSCLC)

  • Integrate recommended approaches to biomarker testing into the management of patients with NSCLC

  • Utilize the results of biomarker testing to identify optimal treatment strategies for patients with advanced NSCLC

Disclosure

Primary Author

Rasheda Persinger, MSN, AGNP-C, AOCNP

Medical Oncology Lead Nurse Practitioner
Sidney Kimmel Cancer Center Sibley Memorial Hospital
Johns Hopkins System
Washington, DC

Rasheda Persinger, MSN, AGNP-C, AOCNP: consultant/advisor/speaker: AstraZeneca, Guardant Health.